Title : Site-specific trastuzumab maytansinoid antibody-drug conjugates with improved therapeutic activity through linker and antibody engineering.

Pub. Date : 2014 Oct 9

PMID : 25191794






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The chemical synthesis of highly stable linker-drugs and the modification of cysteine residues of engineered site-specific antibodies resulted in a homogeneous ADC with increased therapeutic activity compared to the clinically approved ADC, trastuzumab-MCC-DM1. Cysteine immunoglobulin heavy diversity 1-7 Homo sapiens